Sulfonylureas for Treatment of Periodontitis-Diabetes Comorbidity-Related Complications: Killing Two Birds With One Stone

Sulfonylureas for Treatment of Periodontitis-Diabetes Comorbidity-Related Complications: Killing Two Birds With One Stone

Periodontitis is one of the most prevalent oral inflammatory diseases leading to teeth loss and oral health problems in adults. Periodontitis mainly affects periodontal tissue by affecting the host immune system and bone homeostasis. Moreover, periodontitis is associated with various systemic diseas...

Full description

Bibliographic Details
Main Authors:	Luxi Yang, Qing Ge, Zhitong Ye, Lijing Wang, Liping Wang, Mubarak Ahmed Mashrah, Janak L. Pathak
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-09-01
Series:	Frontiers in Pharmacology
Subjects:	periodontitis-diabetes comorbidity sulfonylureas inflammation bone metabolism angiogenesis
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2021.728458/full

Similar Items

Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus – International Task Force
by: Sanjay Kalra, et al.
Published: (2018-01-01)

Sulfonylurea and neuroprotection: The bright side of the moon
by: Nawar R Hussien, et al.
Published: (2018-01-01)

Clinical Characteristics of Subjects with Sulfonylurea-Dependent Type 2 Diabetes
by: Se Hee Min, et al.
Published: (2015-12-01)

Association between obstructive sleep apnea and comorbidities with periodontal disease in adults
by: Catalina Latorre, et al.
Published: (2018-01-01)

Beta-cell function in type 2 diabetic patients who failed to maintain good glycemic status with a combination of maximum dosages of metformin and sulfonylurea
by: Kunavisarut T, et al.
Published: (2019-05-01)

Study of the susceptibility of maize lines to some sulfonylurea herbicides
by: Dragićević Vesna, et al.
Published: (2012-01-01)

Solvent-Free Synthesis and Safener Activity of Sulfonylurea Benzothiazolines
by: Ying Fu, et al.
Published: (2017-09-01)

Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit
by: Chunjiang Wu, et al.
Published: (2015-10-01)

The place of the third generation sulfonylurea glimepiride in modern therapy of type 2 diabetes mellitus
by: L.V. Zhuravlyova, et al.
Published: (2019-03-01)

Some aspects of periodontal disease and comorbid cardiovascular diseases
by: D. I. Trukhan, et al.
Published: (2015-12-01)

Pharmacologically relevant drug interactions of sulfonylurea antidiabetics with common herbs
by: Naina Mohamed Pakkir Maideen, et al.
Published: (2018-07-01)

A Population-Based Study on the Association between Periodontal Disease and Major Lifestyle-Related Comorbidities in South Korea: An Elderly Cohort Study from 2002–2015
by: Jae-Hong Lee, et al.
Published: (2020-10-01)

Relationship between glycated hemoglobin level and duration of hypoglycemia in type 2 diabetes patients treated with sulfonylureas: A multicenter cross‐sectional study
by: Atsuko Matsuoka, et al.
Published: (2020-03-01)

Sulfonylureas and cardiovascular complications of type 2 diabetes mellitus
by: Lyudmila Viktorovna Nedosugova
Published: (2013-06-01)

Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment
by: Yeoree Yang, et al.
Published: (2016-10-01)

Unravelling the utility of modern sulfonylureas from cardiovascular outcome trials and landmark trials: expert opinion from an international panel
by: S. Kalra, et al.
Published: (2020-01-01)

The influence of selected spraying parameters on two formulation of sulfonylurea herbicides effect
by: Renata KIELOCH, et al.
Published: (2013-03-01)

Pharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitus
by: Alla Vsevolodovna Rudakova
Published: (2011-09-01)

Downregulation of Macrophage-Specific Act-1 Intensifies Periodontitis and Alveolar Bone Loss Possibly via TNF/NF-κB Signaling
by: Janak L. Pathak, et al.
Published: (2021-03-01)

Sulfonylureas in type 2 diabetes mellitus: Current evidence, conflicts and clinical implications
by: Chiedozie Kenneth Ugwoke, et al.
Published: (2017-01-01)

Successful sulfonylurea treatment in a patient with permanent neonatal diabetes mellitus with a novel mutation
by: Sung Yeon Ahn, et al.
Published: (2015-08-01)

Curcumin for the Management of Periodontitis and Early ACPA-Positive Rheumatoid Arthritis: Killing Two Birds with One Stone
by: Eleni Asteriou, et al.
Published: (2018-07-01)

Genetic studies on the target-site resistance to sulfonylurea herbicides in Schoenoplectus juncoides
by: Sada, Yoshinao
Published: (2015)

Exposure to trace amounts of sulfonylurea herbicide tribenuron-methyl causes male sterility in 17 species or subspecies of cruciferous plants
by: Cheng-Yu Yu, et al.
Published: (2017-06-01)

Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes
by: Morten Hindsø, et al.
Published: (2021-03-01)

aThe characteristics of glucose metabolism in the sulfonylurea receptor 1 knockout rat model
by: Xiaojun Zhou, et al.
Published: (2019-01-01)

Feasibility of efficacious therapy of diabetes mellitus by sulfonylurea agents in neonates with KCNJII gene mutation: originalobservation
by: Andrey Olegovich Emel'yanov, et al.
Published: (2009-09-01)

Long‐term follow‐up of children with in utero exposure to sulfonylurea medications
by: Marissa S. Rodenstein, et al.
Published: (2021-08-01)

Prevalence of Hypoglycemia, Treatment Satisfaction, Adherence and Their Associations with Glycemic Goals in Patients with Type 2 Diabetes Mellitus Treated with Sulfonylureas: Findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) in Romania
by: Popoviciu Simona, et al.
Published: (2019-03-01)

Dynamics of total volume of pancreatic α‐ and β ‐cells under the influence sulfonylureas and their combination with dipeptidyl peptidase‐4 inhibitors
by: Tuchina Taisiia Pavlovna, et al.
Published: (2021-07-01)

TREATMENT OF THE TYPE 2 OF DIABETES PATIENTS WITH THE SECONDARY FAILURE OF THE ORAL THERAPY: COMPARISON OF THE INSULIN-SULFONYLUREA REGIME AND THAT OF THE INSULIN-METFORMIN
by: Saša Živić, et al.
Published: (2002-09-01)

The frequency of hypoglycemia and cardiovascular disorders during therapy with sulfonylureas compared with other secretagogues: a systematic review
by: Aleksey Vadimovich Zilov, et al.
Published: (2010-06-01)

Periodontal Disease in Association with Systemic Diseases in the Dog
by: Penlington L., et al.
Published: (2019-12-01)

Within-class differences in cancer risk for sulfonylurea treatments in patients with type 2 diabetes (ZODIAC-55) – a study protocol
by: Dennis Schrijnders, et al.
Published: (2017-06-01)

Transformation of Iodosulfuron-Methyl into Ionic Liquids Enables Elimination of Additional Surfactants in Commercial Formulations of Sulfonylureas
by: Witold Stachowiak, et al.
Published: (2021-07-01)

Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy
by: Lorenzoni V, et al.
Published: (2017-11-01)

Evaluation of the efficiency and safety of therapy with a combination of sulfonylurea derivatives and insulin sensitizers for type 2 diabetes mellitus
by: O N Goncharenko, et al.
Published: (2012-08-01)

Successful switching from insulin to sulfonylurea in a 3-month-old infant with diabetes due to p.G53D mutation in
by: Jong Seo Yoon, et al.
Published: (2018-09-01)

Sublethal application of various sulfonylurea and imidazolinone herbicides favors outcrossing and hybrid seed production in oilseed rape
by: Cheng-Yu Yu, et al.
Published: (2020-02-01)

Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes
by: Kiyohiko Takahashi, et al.
Published: (2019-03-01)